SecBot SecBot
8-K ·Filed Nov 5, 2026

MNKD

MANNKIND CORP
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 5h ago SEC0001193125-26-449743
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Furoscix ReadyFlow adoption trajectory and Q4 revenue commentary (management expects Furoscix Q4 revenue to exceed H1 2026 total) are the key near-term catalysts. Monitor the Q4 2026 earnings call for Furoscix revenue, Afrezza pediatric prescription trends, and any update on the inhaled GLP-1 program with Rose Pharma.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

MNKD drug pipeline →

nintedanib DPI

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2 (enrolling)
Time to market
At least 3-5 years away, assuming successful Phase 2 and Phase 3 trials and subsequent regulatory filings
Next catalyst
None dated

What to watchWatch for Phase 2 INFLO-2 enrollment completion updates and eventual topline efficacy data (likely 12-18 months out). For MNKD overall, the approved Afrezza and Furoscix franchises are nearer-term value drivers; nintedanib DPI is a pipeline optionality play. MannKind's analyst consensus is Strong Buy (12 Buy/Strong Buy vs 2 Hold) with a mean price target of $7.97 (84% upside from ~$4.07), but the stock also shows elevated short-volume ratios, indicating debate.

Price Chart

Loading chart...

Executive Summary

MannKind reported Q3 2026 total revenue of $101.9M (+24% YoY), driven by Furoscix ($22.4M, up from zero) and royalties (+12%). GAAP net loss was $23.2M ($-0.07/share) vs. net income of $8.0M a year ago, as SG&A more than doubled to $61.4M to support two commercial launches. The Furoscix ReadyFlow autoinjector was approved and shipments began in mid-September, with rapid adoption reaching ~75% of weekly shipments by late October. No consensus-based EPS or revenue surprise can be computed because the Street consensus of $-0.08 EPS and $108.5M revenue is for a different fiscal quarter (Sep 2026) than the one reported (three months ended Sep 30, 2026).

Key Financial Metrics

EPS (Adj.)
−$0.01
GAAP: $-0.07
Revenue
$101.9M
+24.0% YoY

Key Facts

  • Q3 2026 total revenue $101.9M, +24% vs. Q3 2025
  • Commercial product revenue $45.0M, +102% vs. Q3 2025
  • Furoscix net revenue $22.4M (vs. zero in Q3 2025); ReadyFlow approved and launched mid-September
  • Afrezza net sales $19.3M, +5% YoY; pediatric launch drove ~80% increase in new-to-brand prescriptions QoQ
  • Royalties $37.5M, +12% YoY, driven by United Therapeutics' Tyvaso DPI sales
  • GAAP net loss $23.2M ($-0.07/share) vs. net income $8.0M ($0.03/share) in Q3 2025
  • Non-GAAP adjusted net loss $3.6M ($-0.01/share) vs. non-GAAP net income $22.4M ($0.07/share) in Q3 2025
  • SG&A $61.4M, +111% YoY, due to launch activities for Furoscix ReadyFlow and Afrezza pediatric
  • Cash, cash equivalents and investments $96.6M at Sep 30, 2026
  • Closed $50M private placement on July 24, 2026 to fund $45M CVR payment from Furoscix ReadyFlow approval
  • Entered licensing agreement with Rose Pharma for inhaled GLP-1 for weight management
  • Anticipates $15M in milestone payments from United Therapeutics for ralinepag DPI in 2027

Financial Impact

Revenue growth of $19.7M YoY (+24%), but GAAP net loss widened by $31.2M vs. prior year due to launch-related SG&A spending

revenuenet incomeSG&Acash

Segment Breakdown

SegmentRevenueGrowth
Afrezza$19.3M+5.0%
Furoscix$22.4MNot reported
V-Go$3.3M-14.0%
Collaborations and services$19.4M-27.0%
Royalties$37.5M+12.0%

Risk Factors

  • SG&A more than doubled to $61.4M, raising questions about path to profitability
  • Cash burn continues; cash and investments declined from $134M at Mar 31, 2026 to $96.6M at Sep 30, 2026
  • Furoscix gross margin is lower than Afrezza, pressuring overall margins
  • Collaborations and services revenue declined 27% YoY due to lower product sold to United Therapeutics

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-449743
Document: mnkd-20261105.htm0001193125-26-449743
Document: 0001193125-26-449743-index-headers.html0001193125-26-449743
Document: 0001193125-26-449743-index.html0001193125-26-449743
Document: 0001193125-26-449743.txt0001193125-26-449743
8-K Data (Synthetic)0001193125-26-449743

Track record

17 reports on MNKD

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 5/10 Viewing No price data
  3. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
  4. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
  5. Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
  6. Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
  7. Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
  8. Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
  9. Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
  10. May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026